Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Wednesday . The stock had previously closed at $17.07, but opened at $17.75. Ascentage Pharma Group International shares last traded at $17.65, with a volume of 1,045 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. B. Riley Financial began coverage on Ascentage Pharma Group International in a research note on Wednesday. They set a “buy” rating and a $45.00 target price for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Trading Up 3.4%

The stock has a fifty day moving average price of $22.53 and a two-hundred day moving average price of $24.99. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million during the quarter. As a group, analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds have recently modified their holdings of AAPG. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.